

STD'S AND UTI'S (5/04) 5

Major STD Syndromes

1. Male urethritis
2. Genital ulcer disease
3. Mucopurulent cervicitis
4. Pelvic inflammatory disease
5. Vaginitis

I. Sexually Transmitted Diseases

- A. **Male urethritis** - urethritis is classically defined as the presence of 4 or more PMN's per HPF.
1. **Gonococcal**- Purulent, profuse discharge. Diagnosis is made by gram stain.
 2. **Nongonococcal** slight to moderate, clear, white or gray discharge, often present only in the morning on rising. Dysuria is usually mild. Chlamydia causes 30-50%, the remainder caused by Ureaplasma urealyticum, probably other organisms. Diagnosis made by negative gram stain and culture for gonorrhea
 3. **Postgonococcal**- when tetracycline not given, along with treatment for GC. Same as nongonococcal, chlamydia more common.
 4. **Herpetic** - beefy red urethral meatus, slight to moderate mucoid discharge. Dysuria is severe relative to other findings. The key to the diagnosis is finding the typical skin lesions, which if not already there will develop within 24 hours.
 5. **Diagnosis**
 - a. Clinical presentation
N. gonorrhoeae has a short incubation period (2-5 days) and usually produces a copious, thick, purulent discharge. C. trachomatis has a longer incubation period and usually results in a less profuse, thin, clear or mucoid discharge. A substantial percentage of men with

- chlamydia urethritis may be asymptomatic.
- b. Gram stain
Gram-negative intracellular diplococci will be seen in 95% of symptomatic patients with gonorrhea. Chlamydial urethritis may present with only a few PMNs or may have a negative smear.
 - c. Culture
Culture on select media (Thayer-Martin) for *N. gonorrhoeae* will be positive in 95% of men with gonorrhea (whether or not they are symptomatic). Cell culture is currently the most specific way to definitively diagnose chlamydia infection.
 - d. DNA probe tests
A single swab specimen can be tested for both *N. gonorrhoeae* (95% sensitive, 85% specific) and *C. trachomatis* (80% sensitive, 95% specific)
 - e. Nucleic acid amplification
Highly sensitive and specific for both infections. May be done on urine specimens.
6. Therapy
- a. Therapy for gonorrhea
 - (1) Recommended
 - (a) ceftriaxone 125 mg IM (single dose) or cefixime 400 mg orally (single dose) or ciprofloxacin 500 mg orally (single dose) or ofloxacin 400 mg orally (single dose)
 - (2) Alternatives
 - (a) spectinomycin 2 g IM (single dose) or cefuroxime axetil 1 g orally (single dose)
 - (3) All of the above regimens should be accompanied by treatment for *C. trachomatis* due to the high likelihood of co-infection (10-30%)
 - (4) Partner notification and treatment

- b. Therapy for non-gonococcal urethritis (NGU)
 - (1) Recommended
 - (a) doxycycline 100 mg orally b.i.d. for 7 days or azithromycin 1 g orally (single dose)
 - (2) Alternatives
 - (a) ofloxacin 300 mg orally b.i.d. for 7 days or erythromycin 500 mg orally q.i.d. for 7 days
 - (3) Management of recurrent NGU
 - (a) Retreat with a different regimen
 - (b) Partner evaluation and treatment
 - (c) Consider *Trichomonas vaginalis* or urethral warts
 - (d) Refer repeated treatment failures to an urologist
- 7. Resistance in *N. gonorrhoeae* - a problem in U.S. as well as developing countries - prevalence is increasing in such places as New York, Miami, Los Angeles
 - (a) Penicillinase-producing *Neisseria gonorrhoeae* (PPNG)- plasmid mediated, resistance acquired by a single step
 - (b) Chromosomally mediated resistant gonorrhea (CMRG) - multiple mechanisms, including decreased cell wall permeability, decreased affinity of penicillin-binding proteins - the cumulative result of many chromosomal mutations.
 - (c) Tetracycline resistance - mediated by the *tetM*-containing plasmid, mechanism unclear.
 - (d) All treatment failures should lead you to suspect resistance.
 - (e) New cephalosporins (ceftriaxone, cefixime) or quinolones (ofloxacin, preferred drugs for treating gonorrhoeae).
- 8. Gonococcal resistance in the U.S. (1996)
 - (a) penicillin – 15%
 - (b) tetracycline – 22%
 - (c) ciprofloxacin - .04% were resistant and .5% had intermediate susceptibility
 - (d) ceftriaxone – no resistance
 - (e) cefixime – no resistance

B. Chlamydia trachomatis

1. Clinical syndromes

- a. **Male urethritis** (nongonococcal urethritis, or NGU) Chlamydia are responsible for 30-50% of cases of NGU. The urethral discharge tends to be less purulent and less copious than GC.
- b. **Epididymitis** - Chlamydia is the most common cause of this in sexually active men.
- c. **Mucopurulent cervicitis** - the cervix is usually friable and erythematous, and the discharge is usually indistinguishable from that caused by the gonococcus
- d. **Pelvic Inflammatory Disease** - symptoms tend by comparison to be less severe than those caused by the gonococcus. The sequelae of infertility, tubal occlusion and ectopic pregnancy are as common or more so than from GC. These are the most important long term morbid events associated with clamydial infections.
- e. **Acute urethral syndrome** - in young women who present with dysuria, pyuria and sterile urine cultures.
- f. **Proctitis** - symptoms are indistinguishable from those caused by other organisms.
- g. **Reiter's syndrome** - C. trachomatis has been isolated from the urethra of up to 70% of men with untreated, nondiarrheal Reiter's syndrome and associated urethritis.
- h. **Lymphogranuloma venereum**
 - (1) Endemic in Asia, Africa, South America- about 500 cases/year reported in the U.S.
 - (2) Incubation period 3 days to 3 weeks-the first stage is a small, painless herpetiform ulcer or papule. Only noticed by about 1/3 of patients.Primary genital ulcer in 10% of patients.
 - (3) 2-6 weeks after exposure, the second stage of extensive, painful regional adenopathy begins.The nodes eventually suppurate, and develop multiple draining sinuses. Fistula formation also common.

- (4) Second stage is accompanied by systemic symptoms such as fever, chills, headache, myalgias, etc.
 - (5) The third stage of LGV is represented by chronic ulcerative or infiltrative involvement of local structures causing fibrosis, stricture formation, and abnormal lymphatic drainage.
- 2. Diagnosis of chlamydial infection
 - a. Tissue culture using McCoy or HeLa cells is the gold standard. Positive cultures are identified by visualizing typical intracytoplasmic inclusion bodies stained by Giemsa, iodine or fluorescent monoclonal antibody, stains.
 - b. Rapid diagnostic tests - Microtrak, Chlamydiazyme - useful in screening high-risk populations but may have a high rate of false positives when used in a population with low prevalence.
- C. Complications of Gonococcal and Chlamydial Infections
 - 1. Epididymitis
 - a. Most epididymitis in men under 35 years of age has a sexually transmitted etiology and those patients should be treated for *C. trachomatis* and *N. gonorrhoeae*. (ceftriaxone 250 mg IM once plus doxycycline 100 mg p.o. b.i.d. for 10 days).
 - b. In most men over 35 years, the infection has a urinary tract origin and they should be tested for an STD but treated for coliforms (ofloxacin 300 mg b.i.d. for 10 days).
 - 2. Conjunctivitis
 - May be secondary to autoinoculation with either *N. gonorrhoeae* or *C. trachomatis*
 - 3. Therapy for chlamydia urethritis or non-gonococcal urethritis (NGU)
 - a. Recommended
 - doxycycline 100 mg orally b.i.d. for 7 days
 - or
 - azithromycin 1 g orally (single dose)
 - b. Alternatives
 - Ofloxacin 300 mg orally b.i.d. for 7 days
 - Or

- Erythromycin 500 mg orally q.i.d. for 7 days
- c. Management of recurrent NGU
 - (1) Partner evaluation and treatment
 - (2) Retreat with a second course of doxycycline plus metronidazole for possible *Trichomonas vaginalis*
 - (3) Consider prostatitis
 - (4) Refer treatment failures to a urologist
 - 4. Disseminated Gonococemia
 - a. Most common cause of acute infectious arthritis among sexually active adults.
 - b. Signs-migratory arthralgias and arthritis finally settling in one or two joints; low-grade fever; skin lesions; genital symptoms are frequently absent.
 - c. Signs-tenosynovitis; arthritis: skin lesions erythematous papules frequently with a pustular or necrotic center, usually less than 30 in number, located distally on the extremities.
 - d. Complications (if untreated)-septic arthritis, endocarditis, meningitis.
 - e. Diagnosis-clinical picture; culture of the organism from urethra, throat, or rectum, or from sexual partner. Blood cultures are positive early on. Cultures of joint fluid should be done but are usually negative until late in the course. Pustular skin lesions should be studied as well to rule out other disseminated infections.
 - f. Treatment-see table, p.48
 - 5. Reiter's syndrome
 - a. Seen in men who are HLA B27 or related antigen positive.
 - b. Chlamydia is the "triggering" agent in as many as 70% of cases not related to a GI infection.
 - c. Clinical-asymmetrical arthritis, most commonly involving the large joints of the lower extremities, skin lesions (keratoderma blennorrhagica, circinate balanitis), urethritis (often subclinical), conjunctivitis (usually very mild and evanescent), uveitis is sometimes seen.
 - d. If chlamydia is implicated, treat the patient

and sex partners with doxycycline.

6. Pelvic inflammatory disease / also major syndrome
 - a. The term is most often used to describe acute spontaneously occurring infection ascending from the servix and involving the uterus, fallopian tubes, and broad ligaments
 - (1) Clinically the diagnosis is imprecise. Classically, symptoms proceed from cervical discharge to midline abdominal pain and abnormal vaginal bleeding, to bilateral lower abdominal and pelvic pain to nausea, vomiting, and peritonitis. The pattern as well as severity of symptoms varies between patients.
 - (2) 5-10% will also have perihepatitis
 - (3) 10% with suspected PID have other problems such as appendicitis, endometriosis, ectopic pregnancy, fallopian tube torsion, or corpus luteum bleeding
 - (4) 25% with suspected PID have no laparoscopic evidence of any disease
 - b. Causes of PID
 - (1) Neisseria gonorrhoea
 - (2) Chlamydia trachomatis
 - (3) Mycoplasma hominis
 - (4) Mixed aerobic and anaerobic bacteria
 - (5) 25% have no etiology proven

D. Vaginal Discharge

1. Endocervix involved (cervicitis)
 - a. N. gonorrhoeae. Gram stain 60-70% sensitive, very specific.
 - b. C. trachomatis. May see typical raised, follicular ectropion. Endocervical mucopus seen.
2. Vaginitis
 - a. Candida sp. Identify by positive KOH prep. Discharge tends to be more curdy in appearance. Treat with short-course miconazole or clotrimazole - in recurrent cases may need to treat the partner as well.(white)
 - b. Trichomonas vaginitis - organisms seen on

saline prep with typical motility pattern. Treat with a single 2g dose of metronidazole. Warn about the antabuse reaction.

- c. Nonspecific vaginitis - probably caused by *Gardnerella vaginalis* in combination with anaerobes.(gray)
 - (1) Usual criteria:
 - (a) pH > 4.7
 - (b) presence of clue cells-we mount
 - (c) positive amine test (whiff test) when KOH added Treat with metronidazole 500 BID X 7 days.
 - (d) thin, homogenous discharge.

E. Genital Ulcer Disease

Regardless of the etiology, genital ulcers have been implicated as a co-factor in the sexual transmission of HIV

1. Venereal Causes
 - a. Genital herpes
 - b. Syphilis
 - c. Chancroid
 - d. LGV
 - e. Granuloma inguinale
2. Non venereal
 - a. Trauma
 - b. Fixed drug eruption
 - c. Neoplasia
 - d. Aphthous ulcers
 - e. Non venereal infection
 - f. Behcet's syndrome
 - g. Reiter's syndrome
3. The Big Three:
 - A. Syphilis
 - (1) Review of natural history
 - (a) Primary

Classically described as a painless, cleansed ulcer with indurated margins. Most cases, however, do not fit these "classic" criteria

- (b) Secondary
 - Macular papular rash that preferentially involves the palms and soles (but may occur anywhere), diffuse lymphadenopathy, moth-eaten alopecia.
- (c) Latency
 - Early
 - late
- (d) Tertiary
 - Aortitis, meningoencephalitis, tabes dorsalis, general paresis of the insane
- (2) Diagnosis
 - (a) Darkfield examination
 - 70-80% sensitive in primary syphilis
 - (b) Reagin tests (RPR, VDRL, ART)
 - 70% sensitive in primary syphilis, but 99% sensitive in secondary syphilis. Reactivity may fall over time.
 - (c) Treponemal tests (FTA, MHA-TP)
 - 85% sensitive in primary syphilis, 99% sensitive in secondary or tertiary syphilis.

Table 1			
Sensitivity of serology Tests for Syphilis			
	Primary	Secondary	Late
Nonspecific (RPR, VDRL, etc.)	60-80%	100%	40-90%
Specific (FTA, TPHA, etc.)	60-90%	95-100%	95-100%

- (3) Treatment
 - (a) Primary, secondary or early latent
 - Benzathine penicillin G, 2.4 million units IM (single dose)
 - or
 - doxycycline 100 mg orally b.i.d. for 14 days
 - (b) Late latent, unknown duration, or tertiary
 - Benzathine penicillin G, 7.2 million units IM given in 3 doses of 2.4 million units at 1 week intervals
 - or
 - doxycycline 100 mg orally b.i.d. for 4 weeks

- (c) Special circumstances
 - CNS infection
 - Pregnancy
 - HIV-positive patient
- (4) Serologic response to therapy
 - (a) A two-dilution decrease in titer should be seen 1 year after treatment
 - (b) Recently infected patients may have a more rapid decrease in titer
 - (c) Some patients remain serofast
- B. Genital herpes
 - 1. Natural history
 - a. The most common cause of genital ulcer disease in North America. 80-90% of genital herpes is due to herpes simplex virus type 2.
 - b. Primary infection
Typically the most severe of herpes outbreaks. The vesicular eruption ulcerates, crusts over and heals over 2-3 weeks. The lesions are typically multiple, shallow and painful. Systemic symptoms are common.
 - c. Recurrences
Similar to above, but with less severe lesions, a shorter duration, and less frequent systemic symptoms.
 - d. Most patients with HSV-2 infection have unrecognized manifestations or remain asymptomatic; however, the virus may be transmitted even in the absence of symptoms.
 - 2. Diagnosis
 - a. Viral culture
 - b. Fluorescent antibody microscopy
 - c. Serology (use "type specific" tests)
 - d. Tzank smear
 - 3. Therapy
 - a. First episode
 - acyclovir 200 mg orally 5 times per day for 7-10 days
 - acyclovir 400 mg orally 3 times per day for 7-10 days
 - famciclovir 250 mg orally three times per

day for 7-10 days

b. Recurrent episodes

- Acyclovir 200 mg orally 5 times per day for 5 days
- Acyclovir 400 mg orally t.i.d. for 5 days
- Fanciclovir 125 mg orally b.i.d. for 5 days
- Valacyclovir 500 mg orally b.i.d. for 5 days

c. Suppressive therapy

- i. Indicated for those with 6 outbreaks per year
- ii. Reduces the frequency and severity of recurrences, and reduces the likelihood of asymptomatic viral shedding.

d. Counseling

In the past, patients were counseled to avoid intercourse or use a condom during an outbreak in order to prevent transmission between partners. Now, patients should be counseled to use condoms at all times to reduce the likelihood of transmission.

C. Chancroid

1. Natural history

- a. Etiologic agent is the gram-negative bacillus *Haemophilus ducreyi*
- b. Average incubation period is 3-7 days
- c. Classically described as a painful, ragged edged, soft ulcer with a purulent base. Most cases, however, do not fit this "classic" description.
- d. 30% develop inguinal buboes.

2. There are no commercially available diagnostic tests, so the diagnosis is entirely clinical.

3. Therapy

Ceftriaxone 250 mg IM (single dose)

or

azithromycin 1 g orally (single dose)

or ciprofloxacin 500 mg orally b.i.d. for 3 days

or

erythromycin 500 mg orally q.i.d. for 7 days

D. Inguinal lymphadenopathy and STDs

1. Tenderness

- a. chancroid
- b. LGV
- c. genital herpes
- d. gonorrhea
- e. rarely syphilis

2. Suppurative

- a. chancroid
- b. LGV
- c. rarely genital herpes, syphilis, gonorrhea

3. Bilateral

- a. syphilis
- b. genital herpes
- c. rarely chancroid, LGV

4. Mucopurulent Cervicitis (MPC)

- a. Definition - Inflammation of the endocervix resulting in a thick cervical discharge, erythema and ectopy of the endocervical mucosa, and easily induced bleeding.

b. Pathogens

- (1) *N. gonorrhoeae*
- (2) *C. trachomatis*
- (3) No organism is isolated in many cases.

c. Diagnosis

(1) Clinical presentation

- (a) Signs and symptoms are less specific in women than in men. 30-40% of women with gonorrhea and perhaps >50% with chlamydia may be asymptomatic.
- (b) Bartholin's glands may be involved.
- (c) Acute urethral syndrome (*C. trachomatis*) Young women who present with dysuria, pyuria and negative urine cultures.

(2) Gram stain is not as sensitive for women as for men.

(3) Culture has equal sensitivity in men and women.

- d. Treatment for uncomplicated gonococcal or chlamydial cervicitis in the female patient is

identical to that of urethral infections in the male patient.

5. Pelvic Inflammatory Diseases (PID)

a. Definition - An acute syndrome caused by the ascent of microorganisms from the vagina and endocervix to the endometrium, fallopian tubes and/or contiguous structures. A significant (but unknown) percentage of upper genital tract infections in women, however, may be asymptomatic.

b. Pathogens

- (1) C. trachomatis
- (2) N. gonorrhoeae
- (3) Gardnerella vaginalis
- (4) other facultative aerobes and anaerobes

c. Diagnosis

(1) Clinical criteria

(a) Minimum criteria (all three must be present)

- ✓ lower abdominal tenderness
- ✓ adnexal tenderness
- ✓ cervical motion tenderness

(b) Additional criteria

- ✓ cervical or vaginal discharge
- ✓ oral temperature $> 38.3^{\circ}\text{C}$
- ✓ leukocytosis
- ✓ elevated erythrocyte sedimentation rate or
- ✓ C-reactive protein
- ✓ inflammatory mass on ultrasound
- ✓ endometritis by biopsy
- ✓ purulent aspirate by culdocentesis

(2) Complications

- (a) Tubo-ovarian abscess
- (b) Fitz-Hugh-Curtis syndrome
- (c) Infertility and ectopic pregnancy

(3) Treatment

(a) Criteria for hospitalization

- ✓ pelvic abscess
- ✓ uncertain diagnosis (cannot

Table 2
Relationship Between Number of PID Episodes, Ectopic Pregnancy, and Tubal Infertility in 1539 Women

	Number of PID Episodes			
	0	1	2	≥ 3
Intrauterine pregnancy	433	852	124	24
Ectopic pregnancy (%)	6 (1.3)	61 (9.3)	24 (16)	15 (38)

rule out appendicitis) or
ectopic pregnancy)

- ✓ pregnancy
- ✓ concurrent HIV infection
- ✓ adolescence
- ✓ severe illness
- ✓ inability to follow or tolerate
out-patient regimen
- ✓ lack of a clinical response
after 3 days of outpatient
therapy
- ✓ inability to arrange
appropriate follow-up

(b) Inpatient therapy

- ✓ Recommended cefoxitin 2g
IV every 6 hours or
cefotetan 2 g IV every 12
hours plus doxycycline 100
mg IV every 12 hours
- ✓ This regimen should be
continued for 48 hours after
clinical improvement
develops, then followed with
doxycycline 100 mg orally
b.i.d. to complete a total of
14 days of therapy.

(c) Outpatient therapy

- ✓ Recommended cefixitin 2 g
IM plus probenecid 1 g
orally (single dose) or
ceftriaxone 250 mg IM
(single dose) plus
doxycycline 100 mg orally
b.i.d. for 14 days

9. Vaginitis

a. Conditions and organisms

- (1) Trichomoniasis - *Trichomonas vaginalis*
- (2) Bacterial vaginosis - *Gardnerella vaginalis*, anaerobes
- (3) Vulvovaginal candidiasis - *Candida albicans* (and other species)

b. Trichomoniasis

- (1) Diagnosis

- (a) saline wet prep
- (2) Treatment
 - (a) metronidazole 2 g orally (single dose) or metronidazole 500 mg orally b.i.d. for 7 days
 - (b) treatment of sex partners
 - (c) pregnant women may be treated with single dose of metronidazole
- c. Bacterial vaginosis
 - (1) Diagnosis
 - (a) discharge
 - (b) pH > 4.5
 - (c) whiff test with 10% KOH
 - (d) clue cells on saline wet prep
 - (2) Treatment
 - (a) metronidazole 500 mg b.i.d. for 7 days
or
metronidazole 2 g orally in a single dose
or clindamycin cream 2% 5 g intravaginally qHS for 7 days
or
Metronidazole gel intravaginally b.i.d. for 5 days
 - (b) Partner treatment is not routinely recommended
 - (c) In pregnancy, use of lower dose metronidazole (250 mg t.i.d. for 7 days) is recommended. Delay treatment until the second trimester if possible.
- d. Vulvovaginal candidiasis
 - (1) Diagnosis
 - (a) thick white vaginal discharge
 - (b) pruritus
 - (c) yeast and pseudohyphae on 10% KOH preparation
 - (2) Treatment
 - (a) wide variety of prescription and OTC azole creams for intravaginal use

- (b) fluconazole 150 mg orally in a single dose
- (c) treatment of sex partners is not routinely indicated

10. Human Papillomavirus

A. Incidence

- (1) Over 1 million office visits/year in the U.S.; 200,000 “first time” visits
- (2) Estimated that one-third of sexually active women are infected with HPV, yet the prevalence of genital warts may only be about 1% of the population

B. Manifestations

- (1) Genital warts: condyloma acuminata; smooth papules; keratotic; flat
- (2) Types 6 and 11 are most common, and they are not associated with cervical neoplasia
- (3) Types 16 and 18 are associated with cervical neoplasia

C. Diagnosis is usually made on the basis of clinical examination, but occasionally acetic acid solution (3-5%) is used, or biopsy and pathologic examination are required. HPV typing has not played a role in the management of patients.

D. Treatment

- (1) Observation (up to 28% may resolve on their own)
- (2) Imiquimod cream, 5% (Aldara) – apply at night and wash off in the morning 3 times per week for 8 weeks (safe in pregnancy)
- (3) Podophyllin 10-25% - wash off after 1-4 hours; weekly treatment for 6 weeks
- (4) Podofilox .5% (Condylox) – apply b.i.d. for 3 days, followed by 4 days off; repeat cycle for 4 weeks (not for use in pregnancy)
- (5) Cryotherapy (liquid nitrogen)
- (6) Trichloroacetic acid 85-95% solution applied weekly (safe in pregnancy)
- (7) Electrodesiccation
- (8) Interferon injections

- (9) 5-fluorouracil injection

Treatment of Sexually Transmitted Diseases

Type or Stage	Drug of Choice	Dosage	Alternatives
CHLAMYDIA TRACHOMATIS			
Urethritis, cervicitis, conjunctivitis, or proctitis (except lymphogranuloma venereum)	Doxycycline ¹	100 mg oral bid x 7 days	Erythromycin ² 500mg oral qid x 7d ² Ofloxacin 300 mg oral bid x 7 days Arithromycin 1 gram orally once
Infection in Pregnancy	Erythromycin ²	500 mg oral qid x 7 days ³	Amoxicillin 500 mg oral tid x 10 days Clindamycin 450mg oral qid x 10 days ⁴
❑ Ophthalmia	Erythromycin	12.5 mg/kg oral or IV qid x 14 days	
❑ Pneumonia	Erythromycin	12.5 mg/kg oral or IV qid x 14 days	Sulfisoxazole ⁵ 100 mg/kg/day oral or IV in divided doses x 14 days
Lymphogranuloma venereum	Doxycycline ¹	100 mg oral bid x 21 days	Erythromycin ² 500 mg oral qid x 21 days
GONORRHEA⁶			
Urethral, cervical, rectal, or pharyngeal	Ceftriaxone	125-250 mg IM once	Cefixime 400 mg orally once Ciprofloxacin 500 mg orally once Ofloxacin 400 mg orally once Spectinomycin 2 grams IM once
Ophthalmia (adults) ⁸	Ceftriaxone	1 gram IM once plus saline irrigation	Ceftriaxone 1 gram IV or IM daily x 5 days, plus saline irrigation
Bacteremia and arthritis ⁹	Ceftriaxone	1 gram IV daily x 7-10 days	Ceftizoxime or cefotaxime, 1 gram. IV q8h for 2-3 days or until improved, followed by cefixime 400 mg orally bid or ciprofloxacin 500 mg orally to complete 7-10 days total therapy
Meningitis	Ceftriaxone	2 grams IV daily for at least 10 days	Penicillin G at least 10 million U IV daily for at least 10 days
Endocarditis	Ceftriaxone	2 grams IV daily for at least 3 to 4 weeks	Penicillin G at least 10 million U IV daily for at least 3-4 weeks ¹⁰

1. Or tetracycline 500 mg oral qid
2. Erythromycin estolate is contraindicated in pregnancy.
3. In presence of severe-gastrointestinal intolerance, decrease to 250 mg qid and extend duration to 14 days.
4. Or another sulfonamide in equivalent dosage; avoid all sulfonamides in the third trimester.
5. Only for infants more than four weeks old.
6. Since a high percentage of patients with gonorrhea have coexisting Chlamydia trachomatis infection, all patients should also receive a course of treatment effective for Chlamydia.
7. Not effective for pharyngeal infection.
8. An oral fluoroquinolone, such as ciprofloxacin for 3-5 days, probably would also be effective, but experience is limited.
9. If the infecting strain of N. gonorrhoeae has been tested and is known to be susceptible to penicillin or the tetracyclines, treatment may be changed to penicillin G 10 million U IV daily, amoxicillin 500 mg orally qid, doxycycline 100 mg orally bid, or tetracycline 500 mg orally qid.
10. If infecting strain of N. gonorrhoeae has been tested and is known to be susceptible

Reproduced from The Medical Letter on Drugs and Therapeutics. Dec. 27, 1991, Vol. 33, pp 119-22, by permission from the editor.

Treatment of Sexually Transmitted Diseases

Type or Stage	Drug of Choice	Dosage	Alternatives
GONORRHEA Neonatal			
<input type="checkbox"/> Ophthalmia	Ceftriaxone	125 mg IM once plus saline irrigation	Penicillin G 100,000 U/kg/day IV in 4 doses ¹⁰ x 7 days, plus saline irrigation
	OR Cefotaxime	25 mg/kg IV or IM q8-12h x 7 days, plus saline irrigation	`
<input type="checkbox"/> Arthritis and septicemia	Cefotaxime	25-50 mg/kg IV q8-12h x 10-14 days	Penicillin G 75,000 to 100,000 U/kg/day IV in 4 doses x 7 days ¹⁰
<input type="checkbox"/> Meningitis	Cefotaxime	50 mg/kg IV q8-12h x 10-14 days	Penicillin G 100,000 U/kg/day IV in 8 or 4 doses for at least 10 days ¹⁰
Children (under 45 kg)			
<input type="checkbox"/> Urogenital, rectal and pharyngeal	Ceftriaxone	125 mg IM once	Spectinomycin ⁷ 40 mg/kg/day IM once Amoxicillin 50 mg/kg oral once plus probenecid 25 mg/kg (max. 1 gram) oral once ¹⁰
<input type="checkbox"/> Arthritis	Ceftriaxone	50 mg/kg/day (max. 2 grams) IV x 7 days	Penicillin G 150,000 U/kg/day IV x 7 days ¹⁰
	OR Ceftriaxine	50 mg/kg/day IV in divided doses x 7 days	
<input type="checkbox"/> Meningitis	Ceftriaxone	100 mg/kg/day (max. 2 grams) IV x 7 days	Penicillin G 250,000 U/kg/day IV in 6 divided doses for at least 10 days ¹⁰
	OR Cefotaxime	100 mg/kg/day IV for at least 10 days	Chloramphenicol 100 mg/kg/day IV for at least 10 days
SEXUALLY INFLAMMATORY DISEASE			
	Ceftriaxone followed by doxycycline	250 mg IM once 100 mg oral bid x 10 days	Ciprofloxacin 500 mg or ofloxacin 400 mg orally once followed by doxycycline ¹ 100 mg oral bid x 10 days
PELVIC INFLAMMATORY DISEASE			
<input type="checkbox"/> hospitalized patients	OR Cefoxitin Cefotetan either one plus doxycycline followed by doxycycline ¹	2 grams IV q6h 2 grams IV q12h 100 mg IV q12h until improved 100 mg oral bid to complete 14 days	Clindamycin 900 mg IV q8h plus gentamicin 2 mg/kg IV once followed by gentamicin 1.5 mg/kg IV q8h until improved followed by doxycycline ¹ 100 mg oral bid to complete 14 days ¹¹
<input type="checkbox"/> outpatients	Cefoxitin plus probenecid	2 grams IM once 1 gram oral once	
	OR Ceftriaxone either one followed by Doxycycline ¹	250 mg IM once 100 mg oral bid x 14 days	
VAGINAL INFECTION			
Trichomoniasis	Metronidazole ¹²	2 grams oral once	Metronidazole 500mg oral bid x7days
Bacterial vaginosis	Metronidazole	500 mg oral bid x 7 days	Clindamycin 300mg oral bid x 7 days
Vulvovaginal candidiasis	Topical butoconazole, clotrimazole, miconazole, nystatin, terconazole, or tioconazole ¹³		

11. Or clindamycin 450 mg oral qid to complete 14 days
12. Metronidazole should be avoided during pregnancy but, for pregnant women with severe symptoms, 2 grams oral (single dose) may be given after the first trimester.
13. For preparations and dosage, see The Medical Letter, 33:81, 1991

Treatment of Sexually Transmitted Diseases

Type or Stage	Drug of Choice	Dosage	Alternatives
SYPHILIS			
Early (primary, secondary, or latent less than one year)	Penicillin G benzathine	2.4 million U IM once ¹⁴	Doxycycline ¹ 100mg oral bid x 14 d Ceftriaxone 250 mg IM once daily x 10 days ¹⁵ Erythromycin 500 mg oral qid x 14 days ¹⁶
Late (more than one year's duration, cardiovascular, gumma, late-latent)	Penicillin G benzathine	2.4 million U IM weekly x 3 weeks	Doxycycline ¹ 100 mg oral bid x 4 weeks
Neurosyphilis	Penicillin G	2 to 4 million U IV q4h x 10-14 days	Penicillin G procaine 2.4 million U IM daily plus probenecid 50 mg qid orally, both x 10-14 days
Congenital	Penicillin G	50,000 U/kg IM or IV q8-12 h for 10-14 days	
	OR Penicillin G procaine	50,000 U/kg IM daily for 10-14 days	
CHANCROID	Erythromycin ²	500 mg oral qid x 7 days ³	Ciprofloxacin 500 mg oral bid x 3 days
	OR Ceftriaxone	250 mg IM once ¹⁸	
HERPES SIMPLEX			
First Episode Genital	Acyclovir	400 mg oral tid x 7-10 days	Acyclovir 200 mg oral 5 times/day x 7-10 days
First Episode Proctitis	Acyclovir	800 mg oral tid x 7-10 days	Acyclovir 400 mg oral 5 times/day x 7-10 days
Severe	Acyclovir	5 mg/kg IV q8h x 5-7 days	
Prevention of Recurrences	Acyclovir	400 mg bid	200 mg oral 2-5 times a day

14. Some experts recommend repeating this regimen after seven days, especially in patients with HIV infection.
15. Limited experience; use only if compliance and follow-up are assured
16. Treatment with erythromycin is associated with an increased rate of relapse and should be used only in compliance and 12 months' follow-up are assured and other regimens are contraindicated.
17. Patients allergic to penicillin should be desensitized. Most authorities recommend following either the IV or IM penicillin regimen with benzathine penicillin G 2.4 million units IM weekly x 3 weeks.
18. Single-dose treatment is less effective in HIV-infected patients.
19. Preventive treatment should be discontinued for 1 to 2 months once a year to reassess the frequency of recurrence.